Back to Search
Start Over
Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies
- Source :
- Stem Cells International, Vol 2024 (2024)
- Publication Year :
- 2024
- Publisher :
- Hindawi Limited, 2024.
-
Abstract
- Angiogenesis plays a significant role in the human body, from wound healing to tumor progression. “Angiogenic switch” indicates a time-restricted event where the imbalance between pro- and antiangiogenic factors results in the transition from prevascular hyperplasia to outgrowing vascularized tumor, which eventually leads to the malignant cancer progression. In the last decade, molecular players, i.e., angiogenic biomarkers and underlying molecular pathways involved in tumorigenesis, have been intensely investigated. Disrupting the initiation and halting the progression of angiogenesis by targeting these biomarkers and molecular pathways has been considered as a potential treatment approach for tumor angiogenesis. This review discusses the currently known biomarkers and available antiangiogenic therapies in cancer, i.e., monoclonal antibodies, aptamers, small molecular inhibitors, miRNAs, siRNAs, angiostatin, endostatin, and melatonin analogues, either approved by the U.S. Food and Drug Administration or currently under clinical and preclinical investigations.
- Subjects :
- Internal medicine
RC31-1245
Subjects
Details
- Language :
- English
- ISSN :
- 16879678
- Volume :
- 2024
- Database :
- Directory of Open Access Journals
- Journal :
- Stem Cells International
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.6c5ae565650432d85957c426d8ed980
- Document Type :
- article
- Full Text :
- https://doi.org/10.1155/2024/9077926